• Spore Biotechnologies

  Participated · Series A · Feb 2025

  Founded in 2023, Paris-based Spore Biotechnologies (branded Spore.Bio) builds full-stack platforms that combine proprietary biophotonics hardware with machine-learning models to identify microbes at the single-cell level in real time. Traditional microbiological assays take five to twenty days and require off-site labs; Spore’s solution offers immediate, on-site diagnostics by capturing visible, UV, and near-infrared spectral fingerprints from samples and analyzing them with a foundational model trained on millions of images. The technology integrates with an in-house dashboard that gives manufacturers continuous, traceable insight into microbial activity. To accelerate scientific discovery, the company has created Spore.Labs, an AI-native research arm that will publish open datasets and collaborate with academic and clinical partners. Spore.Bio has raised €29.9 million ($35 million) in equity financing to date, including a €22 million Series A led by Singular in February 2023. The company has begun hiring aggressively, expecting to add 30 scientists by 2026. Its new funding and access to Google Cloud resources further strengthen its R&D and commercialization roadmap.

• Greenbids

  Led · Equity · Jun 2023

  Greenbids is a French sustainable adtech start-up that uses machine learning to identify the most effective media with the lowest carbon footprint, enabling cleaner campaigns on DV360 and Xandr. The platform optimizes advertising delivery to reduce emissions without compromising campaign quality. A Scope3 report cited by the company found digital advertising generates more than 2.6 million metric tons of carbon per year across five leading economies, which underpins Greenbids' mission. The company has partnered with Scope3 to enhance its algorithms with more accurate advertising carbon data. Greenbids plans to use recent funding to grow in the UK and expand its offering to the US. Guillaume Grimbert, co-founder and CEO, says the combined tech and business expertise of the team drives the product and its environmental impact focus.

• Pili

  Participated · Series A · Feb 2023

  PILI is a Toulouse-based startup that produces ecological and financially competitive alternatives to petrochemical dyes and pigments using proprietary fermentation and chemical processes. The company uses local renewable feedstocks—straw, oil, and molasses—to cut CO2 emissions and reduce dependence on Asian imports, aiming to recreate a European supply chain. PILI says it intends to take on the established petro-based indigo industry and decarbonise the broader colour sector. The $15.8 million Series A will be used to further support that decarbonisation and scaling effort. The company reports more than €30 million invested since its creation as it builds capacity to revolutionise colour production globally. Pili develops biobased dyes and pigments via fermentation and sustainable chemistry for textile, plastic, paint and ink sectors. Its technology aims to replace petroleum and polluting chemicals with high-performance, environmentally friendly colors. The company plans to use the €4m funding to scale up production of biobased pigments and to test them in industrial ink and paint formulations. The round brings total investment since founding to €10m and included backers Elaia, SOSV and additional investors. Founded in 2015 and led by CEO Jérémie Blache, Pili emerged from the IndieBio program. The company is based at Toulouse White Biotechnology and at the Conservatoire National des Arts et Métiers in Paris, and its team now numbers more than twenty people. Pili produces biotech dyes and pigments using proprietary fermentation technology and an enzymatic process. Its approach aims to manufacture high-performance bio-based dyes and pigments to reduce the environmental impact of the textile industry. The company has attracted collaboration requests from brands, manufacturers and chemical companies. Founded in 2015 in a biohackerspace, Pili is a Rebel Bio (SOSV) alumni and a member of the Toulouse White Biotechnology consortium. It is led by CEO Jérémie Blache and is based in Toulouse and Paris, France. In March 2019 the company raised €3.6m ($4m) in funding and intends to use the proceeds to strengthen its technological lead and to develop fermentation and green chemistry processes.

• Omi

  Participated · Seed · Jun 2022

  Omi is a Paris-based GenAI SaaS platform that lets brands model products in 3D and instantly create ultra-realistic photos and videos, removing the need for physical productions. Its end-to-end app streamlines imagery workflows, pairs creative freedom with brand control, and enables distribution across channels from a single interface. The company recently launched a 'Generative Videos' feature to give brands enhanced creative control over product visuals. Omi reports having enabled hundreds of global brands, including Clarins and Nestlé, to standardise and accelerate content production. The startup was founded in 2020 by brothers Hugo and Paul Borensztein; Hugo previously worked as a sales executive at Meta. Omi plans to scale globally and launch in the US while further developing its product offering. Omi is a Paris-based provider of a SaaS platform for modelling and rendering photo-realistic 3D photos and videos for brands and marketers. Its proprietary technology enables brands to virtualize products and create photos and videos in minutes with no skills and at low cost. The company already has more than 200 references, from start-ups to international brands including Nestle and Manucurist, and has a strategic partnership with Meta. Led by Hugo Borensztein and Paul Borensztein, Omi plans to use new funding to accelerate R&D and recruit talent. It intends to deploy its international presence with an initial focus on Southern Europe and the UK, and later expand beyond Europe to the United States. The company raised €6m in Seed funding to support these plans.

• Pai

  Led · Series B · Apr 2021

  Pai is an organic skincare company led by founder and CEO Sarah Brown, who remains the majority shareholder. Its flagship product is the Bioregenerate Face Oil, and the brand holds Vegan Society, Cruelty-Free International and London Living Wage accreditations. The company intends to use its new funding to expand West London R&D and manufacturing facilities. Pai also plans to expand its business reach worldwide and to launch new products via its ‘Pai Labs’ innovation hub. The Series B raise strengthens the company’s financial position to support product and manufacturing growth. Leadership and governance will be reinforced with a new board appointment tied to the investment.

No current team members are available.